[1. H. S. White, M. D. Smith and K. S. Wilcox, Mechanisms of action of antiepileptic drugs, Int. Rev. Neurobiol. 81 (2007) 85-110; DOI: 10.1016/S0074-7742(06)81006-82.]Search in Google Scholar
[2. B. S. Meldrum, The role of glutamate in epilepsy and other CNS disorders, Neurology 44 (1994) S14-S23.]Search in Google Scholar
[3. U . Heinemann, D. Kaufer and A. Friedman, Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy, Glia 60 (2012) 1251-1257; DOI: 10.1002/glia.22311.10.1002/glia.22311361524822378298]Search in Google Scholar
[4. D. A. Coulter and T. Eid, Astrocytic regulation of glutamate homeostasis in epilepsy, Glia 60 (2012) 1215-1226; DOI: 10.1002/glia.22341.10.1002/glia.22341337538622592998]Search in Google Scholar
[5. A. Vezzani, J. French, T. Bartfai and T. Z. Baram, The role of inflammation in epilepsy, Nat. Rev. Neurol. 7 (2011) 31-40; DOI: 10.1038/nrneurol.2010.178.10.1038/nrneurol.2010.178337805121135885]Search in Google Scholar
[6. R . M. Kaminski, M. A. Rogawski and H. Klitgaard, The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments, Neurotherapeutics 11 (2014) 385-400; DOI: 10.1007/s13311-014-0266-1.10.1007/s13311-014-0266-1399612524671870]Search in Google Scholar
[7. H. E. Scharfman, Neuroscience. Metabolic control of epilepsy, Science 347 (2015) 1312-1313; DOI: 10.1126/science.aaa9607.10.1126/science.aaa960725792315]Search in Google Scholar
[8. N . Sada, S. Lee, T. Katsu, T. Otsuki and T. Inoue, Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy, Science 347 (2015) 1362-1367; DOI: 10.1126/science.aaa1299.10.1126/science.aaa129925792327]Search in Google Scholar
[9. B. S. Meldrum and M. A. Rogawski, Molecular targets for antiepileptic drug development, Neurotherapeutics 4 (2007) 18-61.10.1016/j.nurt.2006.11.010185243617199015]Search in Google Scholar
[10. A. Plaitakis, P. Flessas, A. B. Natsiou and P. Shashidharan, Glutamate dehydrogenase deficiency in cerebellar degenerations: clinical, biochemical and molecular genetic aspects, Can. J. Neurol. Sci. 20 (1993) S109-S116.10.1017/S0317167100048617]Search in Google Scholar
[11. G. H. Malthankar-Phatak, N. de Lanerolle, T. Eid, D. D. Spencer, K. L. Behar, S. S. Spencer, J. H. Kim and J. C. Lai, Differential glutamate dehydrogenase (GDH) activity profile in patients with temporal lobe epilepsy, Epilepsia 47 (2006) 1292-1299; DOI: 10.1111/j.1528-1167.2006.00543.x.10.1111/j.1528-1167.2006.00543.x16922873]Search in Google Scholar
[12. D. M. Raizen, A. Brooks-Kayal, L. Steinkrauss, G. I. Tennekoon, C. A. Stanley and A. Kelly, Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations, J. Pediatr. 146 (2005) 388-394; DOI: 10.1016/j.jpeds.2004.10.040.10.1016/j.jpeds.2004.10.04015756227]Search in Google Scholar
[13. S . Balasubramaniam, R. Kapoor, J. H. Yeow, P. G. Lim, S. Flanagan, S. Ellard and K. Hussain, Biochemical evaluation of an infant with hypoglycemia resulting from a novel de novo mutation of the GLUD1 gene and hyperinsulinism-hyperammonemia syndrome, J. Pediatr. Endocrinol. Metab. 24 (2011) 573-577.10.1515/jpem.2011.057]Search in Google Scholar
[14. N . Bahi-Buisson, E. Roze, C. Dionisi, F. Escande, V. Valayannopoulos, F. Feillet, C. Heinrichs, B. Chadefaux-Vekemans, B. Dan and P. de Lonlay, Neurological aspects of hyperinsulinism-hyperammonaemia syndrome, Dev. Med. Child. Neurol. 50 (2008) 945-949; DOI: 10.1111/j.1469-8749. 2008.03114.x.]Search in Google Scholar
[15. K. Aso, Y. Okano, T. Takeda, O. Sakamoto, K. Ban, K. Iida, T. Yamano and H. Shintaku, Spectrum of glutamate dehydrogenase mutations in Japanese patients with congenital hyperinsulinism and hyperammonemia syndrome, Osaka City Med. J. 57 (2011) 1-9.]Search in Google Scholar
[16. A. L. Sherwin, Neuroactive amino acids in focally epileptic human brain: a review, Neurochem. Res. 24 (1999) 1387-1395; DOI: 10.1023/A:1022580506443.10.1023/A:1022580506443]Search in Google Scholar
[17. L. A. Vega Rasgado, G. Ceballos Reyes G and F. Vega-Diaz, Anticonvulsant drugs, brain glutamate dehydrogenase activity and oxygen consumption, ISRN Pharmacol. 2012 (2012) 295853-295860.10.5402/2012/295853]Search in Google Scholar
[18. L. A. Vega Rasgado, G. Ceballos Reyes G and F. Vega-Díaz, Effect of convulsant drugs in GDH activity and oxygen consumption in mouse brain, J. Med. Med. Sci. 4 (2013) 34-42]Search in Google Scholar
[19. H. J. Strecker, Glutamic dehydrogenase, Arch. Biochem. Biophys. 46 (1953) 128-140; DOI: 10.1016/0003-9861(53)90176-3. 10.1016/0003-9861(53)90176-3]Search in Google Scholar